In August 2025, the US Food and Drug Administration (FDA) approved brensocatib, marking the first-ever approved therapy for non–cystic fibrosis bronchiectasis. The approval was based on the phase 3 ASPEN trial, the largest study ever conducted in bronchiectasis, enrolling 1,721 patients worldwide. HCPLive spoke with James Chalmers, MBChB, PhD, professor of respiratory research at the University of Dundee and investigator in the ASPEN trial, to learn more about the significance of the approval and the data supporting it. He also touched on how brensocatib is set to reshape care for bronchiectasis and what its approval means for both clinicians and patients moving forward. These findings not only demonstrate clinical benefit but also validate neutrophil-driven inflammation as a therapeutic target in bronchiectasis.